Organon & Co | OGN - Passivo Circulante





Passivo Circulante Alterar Data
Bristol-Myers Squibb USD 18.75B 94M 2026-09
Celltrion KRW 288.01B 4.7B 2026-06
Cspc Pharmaceutical CNY 10.18B 65.36M 2025-12
Deva Holding AS TRY 6.43B 1.18B 2023-09
Dianthus Therapeutics USD 34.39M 3.89M 2026-06
Divis Laboratories Ltd INR 20.43B 3.15B 2026-03
Gilead Sciences USD 12B 982M 2026-09
Glaxosmithkline GBP 20.72B 1.71B 2026-09
Kangmei Pharma CNY 5.1B 280.48M 2026-06
Knight Therapeutics CAD 165.26M 12.58M 2025-12
Laboratorios Farma EUR 199.84M 121.75M 2023-12
Malin Corporation EUR 1000K 500K 2024-12
Medical Developments International AUD 5.56M 2.26M 2025-12
Merck USD 27.73B 786M 2026-06
Neuren Pharmaceuticals AUD 4.34M 3.58M 2025-12
Novartis USD 32.52B 1.15B 2026-09
Organigram Holdings CAD 107.28M 18.54M 2026-06
Organon & Co USD 2.65B 36M 2026-09
Ovoca Bio EUR 1.3M 1.11M 2025-12
Pharma Mar EUR 125.39M 26.97M 2026-09
Qiagen NV USD 581.45M 102.34M 2026-06
Sartorius EUR 1.55B 102.8M 2026-09
Sino Biopharmaceutical CNY 24.85B 5.29B 2025-06
Tilray USD 259.32M 8.32M 2025-09
Zealand Pharma A/S 404M 260.96M 2026-03